AKT1 and metabolic dysfunction-associated steatotic liver disease: In NAFLD, FPR1 can regulate the expression of hnRNP U to promote lipid oxidation and activate the Akt pathway to inhibit hepatic gluconeogenesis [27], thereby improving lipid metabolism in NAFLD.